6505--Tamsulosin Capsules
ID: 36E79725R0011Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/b6e8b7008c97450f89df070be8f19554/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the procurement of Tamsulosin Hydrochloride capsules as part of its Pharmaceutical Prime Vendor (PPV) Programs. Offerors are required to submit pricing for a base year and four option years, ensuring compliance with FDA standards and providing a unique 11-digit National Drug Code (NDC) for each product. This procurement is vital for maintaining a consistent supply of necessary pharmaceuticals to federal healthcare facilities, adhering to regulatory standards while ensuring availability and pricing stability. Interested parties must submit their offers by February 24, 2025, at 2:30 PM CST, and can contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further information.

    Point(s) of Contact
    Andrew J CazaresContract Specialist
    Andrew.Cazares@va.gov
    Files
    Title
    Posted
    36E79725R0011_1.docx
    The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0011 concerning the procurement of Tamsulosin Hydrochloride (HCL) Capsules. This procurement is intended to supply the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and other federal facilities with this medication. One contract will be awarded to a responsible offeror capable of ensuring an uninterrupted supply over a base period of one year, with four optional one-year extensions. Offerors must provide specific product details, including a unique National Drug Code (NDC) and adhere to specified packaging requirements, including safety-cap bottles. The solicitation will be released in electronic format on or about January 7, 2025, with responses due by January 21, 2025. Estimated annual usage includes approximately 1.4 million bottles of 90-count Tamsulosin HCL 0.4mg capsules and additional requests for larger packaging sizes. The presolicitation highlights the VA's commitment to ensuring consistent medicinal supply to support veteran healthcare needs. Interested vendors are encouraged to check the SAM.gov for updates and to direct inquiries to the provided contracting officer.
    36E79725R0011.docx
    The document outlines a solicitation by the Department of Veterans Affairs for the procurement of pharmaceutical products aimed at establishing a supply source for drugs under the Pharmaceutical Prime Vendor (PPV) Programs. It details the contract requirements, including submission guidelines, eligibility criteria for offerors, and specifications for pharmaceutical products such as Tamsulosin HCL capsules. The contract encompasses a base year and four option years, with specific conditions for pricing, compliance with FDA standards, and the necessity of a unique National Drug Code (NDC) for each product. Moreover, it mandates a 0.5% Cost Recovery Fee, reporting obligations for contract sales, and adherence to the Drug Supply Chain Security Act (DSCSA). The contractor is required to maintain acceptable Good Manufacturing Practices (cGMP) and is responsible for notifying the contracting officer of any compliance issues. The document serves as an essential framework to ensure that federal healthcare facilities acquire necessary pharmaceuticals in alignment with regulatory standards while maintaining consistent availability and pricing. Additionally, it highlights the notability of establishing productive supplier relationships crucial for governmental operations.
    36E79725R0011 0001.docx
    The document is an amendment to a solicitation from the Department of Veterans Affairs regarding a request for proposals related to pharmaceutical supply. Specifically, the amendment extends the deadline for offers from February 10, 2025, to February 24, 2025, at 2:30 PM CST. It also corrects the drug name in the schedule of supplies. The solicitation involves Tamsulosin Hydrochloride capsules, indicating that one award will be made based on pricing for line items specified within the solicitation. Offerors are required to provide a price for both the base year and four optional extension years, and must include a Cost Recovery Fee of 0.5%. In addition, it mandates each offered drug includes a unique 11-digit National Drug Code (NDC). The document maintains all other terms and conditions as unchanged, reinforcing the structured protocol typical in government contracting processes. This amendment ensures clarity and fairness in the solicitation process, enabling the Department of Veterans Affairs to procure necessary pharmaceuticals effectively while adhering to established regulations.
    Lifecycle
    Title
    Type
    6505--Tamsulosin Capsules
    Currently viewing
    Solicitation
    6505--Tamsulosin Capsules
    Presolicitation
    Similar Opportunities
    6505--Mycophenolate Mofetil RFP
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) numbered 36E79725R0010 for the procurement of Mycophenolate Mofetil tablets and capsules, intended for use by the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The procurement aims to secure a reliable source of supply for these essential medications, with a contract term of one year and the option to extend for four additional years, emphasizing the importance of uninterrupted access to critical pharmaceuticals for veterans and associated federal programs. Interested offerors must comply with specific packaging requirements, including child-resistant closures for smaller bottles, and are encouraged to check the designated URL for updates, with the solicitation expected to be issued around February 14, 2025, and offers accepted until February 28, 2025. For inquiries, potential bidders can contact Amber Zavala at amber.zavala@va.gov or by phone at (708) 786-5245.
    6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Fluticasone Propionate 50 MCG/Spray solution, nasal, 16GM, intended for use by various federal agencies including the Department of Defense, Bureau of Prisons, and Indian Health Service. The objective of this procurement is to secure a reliable and uninterrupted supply of this medication for a contract period of one year, with the possibility of four additional one-year extensions. This medication is crucial for treating nasal conditions, and the estimated annual requirement is approximately 5,784,828 bottles. The solicitation will be available electronically on or around February 11, 2025, with a closing date set for February 25, 2025. Interested vendors should direct inquiries to Michael Olszewski at michael.olszewski@va.gov or call 708-786-4966.
    6505--Phenytoin SA Capsules (VA-25-00022318)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the procurement of Phenytoin Sodium Extended 100MG Sustained Action Capsules, designated as solicitation number 36E79725R0016. This unrestricted contract aims to ensure a reliable supply of these essential medications for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with one contract awarded for an initial period of one year and the option for four additional one-year periods. The estimated annual requirement is approximately 16,653 units, highlighting the critical need for uninterrupted supply to support service members and associated organizations. Interested offerors should submit their proposals by March 7, 2025, following the electronic issuance of the RFP on or about February 21, 2025, and may direct inquiries to Contract Specialist Youlanda Duggar at youlanda.duggar@va.gov.
    6505--Bevacizumab Injection
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to procure Bevacizumab Injections through a Request for Proposal (RFP) designated as 36E79725R0019. This procurement aims to secure an uninterrupted supply of Bevacizumab, a critical pharmaceutical product used in the treatment of various medical conditions, for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will span one year with four additional one-year option periods, and the estimated annual requirements include various package sizes of Bevacizumab, with a total estimated usage of over 100,000 vials. Interested offerors must submit their proposals by March 4, 2025, at 2:30 PM Central Time, and can direct inquiries to Contract Specialist Matthew Poulin at Matthew.Poulin@va.gov or by phone at 708-786-5186.
    6505--Baclofen Tablets (VA-25-00026620)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the supply of Baclofen Tablets under the solicitation titled "6505--Baclofen Tablets (VA-25-00026620)." The primary objective of this procurement is to establish a reliable source for various strengths of Baclofen tablets, ensuring consistent availability and quality at pre-negotiated prices, while complying with the Drug Supply Chain Security Act and Good Manufacturing Practices. This contract is crucial for maintaining the pharmaceutical needs of VA facilities, addressing issues such as compliance, backorders, and recalls. Interested offerors must submit their proposals by February 5, 2025, at 2:30 PM CST, and can direct inquiries to Contracting Officer Adrienne A Albachiara at Adrienne.Albachiara@va.gov.
    6505--Domestic Pharmaceuticals/Med/Surge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is conducting a Sources Sought notice to identify qualified domestic pharmaceutical manufacturers capable of supplying a range of medications for the Consolidated Mail Outpatient Pharmacy (CMOP). The procurement aims to ensure a reliable supply of domestically manufactured pharmaceuticals, including glucose test strips, hypertension treatments, and various other essential medications. This initiative is crucial for maintaining the health and well-being of veterans, as it supports ongoing healthcare needs. Interested manufacturers must submit their capability statements by February 5, 2025, to Josie Linaweaver at josie.linaweaver@va.gov, and are reminded to register in the System for Award Management (SAM) prior to contract award.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Prescription-fill services
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the VISN 15 Network Contracting Office, is seeking qualified contractors to provide prescription-fill services for eligible veterans at the Harry S. Truman Memorial Veterans’ Hospital (HSTMVH) and its associated community-based outpatient clinics (CBOCs) and Home Based Primary Care (HBPC) program, starting June 1, 2025. The contractor will be responsible for filling and dispensing medications, offering patient counseling, and ensuring compliance with Joint Commission standards while maintaining operations during specified hours. This initiative is crucial for enhancing access to pharmacy services for veterans, thereby prioritizing their health and medication management. Interested parties must submit their responses, including company information and capabilities, to Steve Parrott at stephen.parrott@va.gov by February 7, 2025, at 10:00 AM CST, as this is a Request for Information (RFI) and not a solicitation.
    6505--Rituximab and Biosimilars
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) designated as 36E79725R0021 for the procurement of Rituximab and its biosimilars, aimed at ensuring a reliable supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will span one year with four additional one-year options, emphasizing the necessity of maintaining an uninterrupted supply chain for these critical medications. Offerors must provide the exact product names along with unique National Drug Codes (NDC), with estimated annual requirements of 17,858 vials of Rituximab 10mg/ml and 25,111 vials of the 50mg/ml variant. The solicitation is expected to be published around February 17, 2025, with a closing date around March 4, 2025; interested parties should direct inquiries to Deb Fassl at Deborah.Fassl@va.gov.